{
  "disease": "breast cancer",
  "verdict_date": "2026-02-14",
  "court_session": "Breast Cancer Drug Repurposing Evidence Court",
  "judge": "DrugRescue AI Judge",
  "total_candidates_evaluated": 7,
  "evidence_sources": [
    "ClinicalTrials.gov (terminated/withdrawn trials)",
    "FDA FAERS (adverse event database, inverse signal screening)",
    "Known clinical trial history (literature search tool unavailable)",
    "Molecular structure analysis (similarity and mechanism-based)"
  ],
  "verdicts": [
    {
      "drug_name": "TEMOZOLOMIDE",
      "rescue_score": 71,
      "confidence": 0.65,
      "tier": "Tier 1 \u2014 Prime Candidate",
      "strengths": [
        "91.4% FAERS protective signal is the strongest in the entire screen (p=1.78e-12)",
        "Alkylating agent mechanism \u2014 same class as cyclophosphamide (approved for breast cancer)",
        "BRCA1/2-mutated breast cancers have DNA repair deficiencies that TMZ could exploit",
        "MGMT promoter methylation in ~30% of TNBC creates a biologically defined target population",
        "FDA-approved with oral formulation and well-characterized safety profile"
      ],
      "risks": [
        "Only 8 FAERS co-reports \u2014 sample too small for reliable clinical inference",
        "Zero breast cancer clinical trials in 25+ years since FDA approval",
        "Myelosuppression overlaps with anthracyclines and taxanes \u2014 additive toxicity risk",
        "BBB penetration irrelevant for breast cancer",
        "MGMT status not routinely tested in breast cancer"
      ],
      "verdict": "PURSUE with caution \u2014 prime candidate requiring prospective validation",
      "investment_recommendation": "PURSUE: Fund Phase I/II basket trial in BRCA-mutated or MGMT-methylated TNBC. Estimated cost $180-250M over 3-5 years.",
      "timeline_estimate": "3-5 years",
      "next_steps": [
        "Retrospective analysis of TMZ-treated glioblastoma patients for breast cancer incidence",
        "Design Phase I dose-finding study in BRCA-mutated TNBC with MGMT stratification",
        "Evaluate TMZ + PARP inhibitor combination in preclinical TNBC models",
        "Establish MGMT methylation testing protocol for breast cancer tissue"
      ],
      "dimension_scores": {
        "kg_signal": {
          "score": 95,
          "weight": 0.15
        },
        "trial_safety": {
          "score": 40,
          "weight": 0.2
        },
        "faers_signal": {
          "score": 90,
          "weight": 0.25
        },
        "literature": {
          "score": 45,
          "weight": 0.25
        },
        "molecular": {
          "score": 55,
          "weight": 0.15
        }
      }
    },
    {
      "drug_name": "ETOPOSIDE",
      "rescue_score": 52,
      "confidence": 0.55,
      "tier": "Tier 2 \u2014 Secondary Candidate",
      "strengths": [
        "90.1% FAERS protective signal with robust n=34 co-reports",
        "TOP2A gene amplified in 5-10% of breast cancers (HER2+ subtype)",
        "FDA-approved with decades of clinical experience",
        "Oral formulation available"
      ],
      "risks": [
        "Already tried in breast cancer in 1980s-1990s \u2014 inferior to anthracyclines",
        "Secondary leukemia risk (AML, 1-3%) unacceptable for good-prognosis patients",
        "No modern trials \u2014 FAERS signal may reflect survivor bias",
        "Large molecule with variable oral absorption \u2014 poor PK",
        "No commercial sponsor interest in reviving a generic drug",
        "If TOP2 inhibition worked, doxorubicin would already cover this mechanism"
      ],
      "verdict": "INVESTIGATE FURTHER \u2014 deprioritize behind temozolomide",
      "investment_recommendation": "INVESTIGATE: Consider only in TOP2A-amplified, anthracycline-refractory niche. Cost ~$100-200M. Unlikely to attract commercial sponsorship.",
      "timeline_estimate": "4-6 years",
      "next_steps": [
        "Retrospective analysis of TOP2A-amplified breast cancers treated with etoposide",
        "Preclinical comparison: etoposide vs doxorubicin in TOP2A-high models",
        "Explore academic-sponsored trial"
      ],
      "dimension_scores": {
        "kg_signal": {
          "score": 98,
          "weight": 0.15
        },
        "trial_safety": {
          "score": 30,
          "weight": 0.2
        },
        "faers_signal": {
          "score": 85,
          "weight": 0.25
        },
        "literature": {
          "score": 50,
          "weight": 0.25
        },
        "molecular": {
          "score": 35,
          "weight": 0.15
        }
      }
    },
    {
      "drug_name": "DASATINIB",
      "rescue_score": 48,
      "confidence": 0.5,
      "tier": "Tier 2 \u2014 Secondary Candidate",
      "strengths": [
        "79.7% FAERS protective signal with n=34 co-reports",
        "SRC kinase overactivated in TNBC \u2014 validated preclinical target",
        "Multiple Phase II trials demonstrated some activity",
        "FDA-approved oral TKI with multi-kinase profile",
        "Moderate structural similarity to lapatinib (Tanimoto 0.40)",
        "Potential in rational combinations with immunotherapy"
      ],
      "risks": [
        "Phase II breast cancer trials did NOT lead to approval \u2014 efficacy insufficient",
        "Bristol-Myers Squibb abandoned breast cancer development ~2015",
        "Single-agent ORR 4.7% in TNBC is clinically meaningless",
        "Pleural effusions in 10-30% \u2014 dose-limiting toxicity",
        "If SRC inhibition were sufficient, it would already be approved",
        "Prior Phase II failures represent ~$50-100M in sunk costs",
        "Poor oral bioavailability (34%) requires BID dosing"
      ],
      "verdict": "CONDITIONAL \u2014 only in novel combinations",
      "investment_recommendation": "CONDITIONAL: Do not repeat monotherapy trials. Pursue dasatinib + pembrolizumab or + olaparib in TNBC. Cost ~$200-350M.",
      "timeline_estimate": "4-6 years",
      "next_steps": [
        "Retrospective: CML patients on dasatinib \u2014 breast cancer incidence?",
        "Preclinical: dasatinib + anti-PD-1 in TNBC models",
        "Biomarker-selected Phase II: SRC-high TNBC with combination therapy"
      ],
      "dimension_scores": {
        "kg_signal": {
          "score": 93,
          "weight": 0.15
        },
        "trial_safety": {
          "score": 25,
          "weight": 0.2
        },
        "faers_signal": {
          "score": 70,
          "weight": 0.25
        },
        "literature": {
          "score": 60,
          "weight": 0.25
        },
        "molecular": {
          "score": 55,
          "weight": 0.15
        }
      }
    }
  ],
  "overall_findings": {
    "critical_finding": "FAERS inverse signal screening identified 3 non-breast-cancer drugs with strong protective signals: TEMOZOLOMIDE (91.4%), ETOPOSIDE (90.1%), DASATINIB (79.7%). This demonstrates FAERS utility for hypothesis generation in diseases where traditional repurposing approaches (dropped/withdrawn drugs) yield no candidates.",
    "key_tension": "Statistically significant FAERS protective signals vs absence of prospective clinical validation. Strong statistics do not guarantee clinical efficacy.",
    "methodology_limitations": [
      "Zero dropped/withdrawn drugs \u2014 all candidates are novel, not repurposed failures",
      "Literature search unavailable (Perplexity API key not configured)",
      "Molecular docking unavailable (NVIDIA API key not configured)"
    ]
  },
  "court_recommendations": {
    "advocate_ammunition": [
      "TEMOZOLOMIDE: Emphasize 91.4% protective signal (strongest in screen). Highlight alkylating mechanism similarity to cyclophosphamide (approved for breast cancer). Stress BRCA mutation prevalence in breast cancer (10-15% hereditary, 25% TNBC) creates synthetic lethality opportunity with PARP inhibitors. Emphasize NO breast cancer trials found = untapped opportunity.",
      "ETOPOSIDE: Emphasize 90.1% protective signal with robust n=34 co-reports. Highlight TOP2A amplification in HER2+ breast cancer (5-10% of cases). Stress FDA-approved drug with known safety. Argue for revisiting in anthracycline-refractory, TOP2A-amplified niche indication.",
      "DASATINIB: Emphasize 79.7% protective signal. Highlight SRC mechanism validated in TNBC. Stress Phase II trials showed SOME activity (44% ORR in combination). Argue for modern immunotherapy combinations (PD-1/PD-L1) that weren't available in 2008-2015 trials."
    ],
    "skeptic_ammunition": [
      "TEMOZOLOMIDE: Emphasize only 8 FAERS co-reports (tiny absolute number, possible statistical noise). Highlight zero breast cancer clinical trials = pure speculation. Stress BBB penetration (glioblastoma advantage) wasted in breast cancer. Question why no one has tried it if mechanism is so applicable.",
      "ETOPOSIDE: Emphasize this drug was ALREADY tried 30-40 years ago and FAILED to become standard. Highlight inferior to anthracyclines in head-to-head trials. Stress secondary leukemia risk (1-3%) unacceptable. Argue FAERS signal likely survivor bias (younger patients with other cancers).",
      "DASATINIB: Emphasize Phase II trials FAILED - Bristol-Myers Squibb walked away for a reason. Highlight 4.7% single-agent ORR is clinically meaningless. Stress 44% ORR in combination showed NO OS benefit. Highlight pleural effusions (10-30%) as severe quality of life impact. Argue if SRC inhibition worked, it would already be approved."
    ]
  },
  "dissenting_notes": {
    "disagreement_with_advocate": [
      "FAERS protective signals are hypothesis-generating, not confirmatory. The 91.4% signal for TMZ is based on only 8 co-reports.",
      "The absence of breast cancer trials for TMZ is not an untapped opportunity \u2014 it reflects expert consensus that preclinical data was insufficient."
    ],
    "disagreement_with_skeptic": [
      "The skeptic's 'if it worked, someone would have tried it' argument ignores systematic biases in drug development toward profitable molecules.",
      "Dasatinib's 4.7% ORR as monotherapy does not preclude efficacy in rational combinations with immunotherapy or PARP inhibitors."
    ]
  },
  "verdict_summary": "TEMOZOLOMIDE is the prime repurposing candidate (score 71/100) based on strongest FAERS signal and mechanistic rationale in BRCA-mutated tumors. ETOPOSIDE (52/100) and DASATINIB (48/100) are secondary with known but limited clinical histories."
}